This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nagaya, N. Articles by Kunieda, T. Search for Related Content PubMed PubMed Citation Articles by Nagaya, N. Articles by Kunieda, T.

Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension

Noritoshi Nagaya, MD^*, Masaaki Uematsu, MD, PhD, Yoshiaki Okano, MD, Toru Satoh, MD, PhD^*, Shingo Kyotani, MD, PhD^*, Fumio Sakamaki, MD, PhD^*, Norifumi Nakanishi, MD, PhD^*, Kunio Miyatake, MD, PhD, FACC^* and Takeyoshi Kunieda, MD, PhD

^* Division of Cardiology, Department of Medicine, National Cardiovascular Center, Osaka, Japan
Cardiovascular Division, Osaka Police Hospital, Osaka, Japan
Department of Clinical Laboratory Medicine, Kyoto University Hospital, Kyoto, Japan
Department of Medicine, Ise Keio Hospital, Keio University, Mie, Japan

View larger version (20K): [in a new window]   Figure 1 Long-term effects of beraprost sodium on: (A) mean pulmonary arterial pressure (mPAP), (B) cardiac output (CO) and (C) total pulmonary resistance (TPR).

View larger version (16K): [in a new window]   Figure 2 Kaplan-Meier survival curves showing that outpatients treated with beraprost sodium (BPS) have a significantly higher survival rate than those treated with conventional therapy (log-rank test, p < 0.001).